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Department of Lung Medicine, University Hospital, Trondheim, Nonoay 
Asthma-like symptoms and bronchial hyper-responsiveness (BHR) to methacholine are prevalent in competitive 
cross-country skiers. Whether these symptoms (ski asthma) in these athletes are caused by asthma remains 
uncertain. 
Bronchial responsiveness to adenosine S-monophosphate (AMP) and nitric oxide (NO) concentration in exhaled 
air, both indirect markers of asthmatic airway inflammation, were investigated in two non-smoking study 
populations of skiers and asthmatics. 
Of 18 skiers with ski asthma, 15 non-steroid and 14 steroid-treated asthmatics, BHR to AMP was present in five 
(28%), six (40%) and 10 (71%) subjects respectively. Although the groups were not significantly different in 
responsiveness to methacholine, responsiveness to AMP increased in order of magnitude from ski asthma -C non- 
steroid-treated < steroid-treated asthma. Exhaled NO in 44 (nine with ski asthma) skiers was not significantly 
different from 82 healthy non-atopic controls [median [interquartile range (IQR)] 6.5 (4.1-9.9) vs. 5.2 (4.2-6.5) ppb]. 
Exhaled NO in 29 subjects with mild intermittent asthma was three-fold greater [median (IQR) 19.2 (5.1-25.6) ppb, 
P < 0.011 than in skiers. Exhaled NO was two- and four-fold greater in atopic than non-atopic subjects in the skier 
(P~O.001) and asthmatic (P~0.01) groups, respectively, and was correlated to methacholine responsiveness in 
atopic asthmatics (n = 22, rho = 0.55, P < 0.01). 
Exhaled NO was not elevated in ski asthma and may be more useful as a marker of atopic status than 
inflammation in the lower airway in skiers. Few skiers were hyper-responsive to AMP, indicating that pre-activated 
mucosal mast cells are not a predominant feature in ski asthma. 
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htroduction 
Exercise can trigger acute bronchospasm in asthmatics. 
This effect of exercise is potentiated by simultaneous 
exposure to cold air (1). Highly trained athletes are 
reported to have a high prevalence of bronchial hyper- 
responsiveness to methacholine and exercise, asthma-like 
symptoms, use of anti-asthmatic medication and asthma 
(2,3,4). Moreover, cross-country skiers commonly report 
obstructive airway symptoms with co-existent hyper- 
responsiveness to methacholine (5,6). 
Although associated with airway inflammation in asth- 
ma, bronchial hyper-responsiveness to methacholine is not 
specific to asthma, as it can also be present in healthy 
subjects during viral infections and in patients with other 
respiratory diseases (7,8,9). However, inhalation of adeno- 
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sine 5’-monophosphate (AMP) also provokes bronchocon- 
striction in asthmatic subjects. This effect is believed to be 
mediated through release of mediators from pre-activated 
mast cells situated in the bronchial mucosa (10). Thus, 
hyper-responsiveness to AMP is believed to be more 
specific (11,12) and a more sensitive marker for assessing 
airway wall inflammation in asthma (13,14) compared to 
methacholine. Another promising, indirect marker of 
airway inflammation is the concentration of nitric oxide 
(NO) in exhaled air. The measurement of exhaled NO is 
easy to perform and is non-invasive. Increased levels have 
been reported in normal individuals with upper respiratory 
tract infections (15) and in patients with asthma, especially 
those with allergic asthma (16,17). A further increase can be 
seen in relation to asthma exacerbation, with normalization 
often occurring either spontaneously or after steroid 
treatment (18,19). As uncertainty exists as to whether 
asthma is present in athletes with bronchial hyper-respon- 
siveness to methacholine and obstructive symptoms (20) the 
aims of this two-part study were to investigate the bronchial 
responsiveness to AMP and the concentration of exhaled 
NO in skiers with ski asthma. 
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TABLE 1. Subject characteristics 
AMP study Nitric oxide study 
Ski asthma Asthmatics Controls Skiers Asthmatics 
Steroid - Steroid+ 
n (males) 18 (10) 15 (5) 14 (2) 82 (37) 44 (25) 29 (12) 
Age-mean (range) years 18.5 (16-27) 17.5 (16-31) 37.7 (18-61) 16.0 (13-19) 17.4 (16-20) 16.5 (13- 19) 
Atopy (%) 7 (39%) 10 (67%) 10 (71%) 0 (0%) 13 (30%) 22 (76%) 
BHR methacholine (Oh) 18 (100%) 15 (100%) 14 (100%) 0 (0%) 9 (21%) 29 (100%) 
Asthma medication (%) 7 (39%) 9 (60%) 14 (100%) 0 (0%) 8 (18%) 17 (59%) 
&agonist as required 6 (33%) 9 (60%) 13 (93%) 0 6 (14%) 17 (59%) 
Cromolyn as required 1 (6%) 0 0 0 2 (4%) 0 (0%) 
Topical steroid 0 0 14 (100%) 0 0 0 
Theophylline 0 0 1(7%) 0 0 0 
Baseline FEV, (% predicted) 
Methacholine-mean (SD) 100.4 (9.9) 106.2 (11.2) 94.9 (11.3)# 113.4 (12.5) 96.2 (11.3)““** 106.3 (14.3)* 
AMP-mean (SD) 97.5 (9.6)# 107.9 (13.7) 96.2 (9.6)# NA NA NA 
Steroid -: non-steroid treated asthmatics; steroid f: steroid-treated asthmatics. *P<O.O5 vs. Controls. **P<O.Ol, skiers v,s. 
Asthmatics, ***P< 0.001 vs. Controls vs. Asthmatics (one-way ANOVA) #P<O.O5 vs. Steroid - asthmatics (one-way 
ANOVA) AMP: adenosine S’monophosphate. BHR: bronchial hyper-responsiveness, NA: not applicable. 
Methods 
SUBJECTS 
Competitive cross-country skiers, asthmatics and healthy 
controls were recruited to the study. All subjects were 
non-smokers and had no history of an upper respiratory 
tract infection within the 3 weeks prior to participation in 
the study. All subjects, as well as the parents of those 
subjects less than 18 years of age, gave written informed 
consent to the study, which was approved by the Regional 
Ethics Committee in Trondheim. 
Two separate study populations were investigated 
(Table 1). The study population for assessment of bronchial 
responsiveness to AMP consisted of 18 skiers and 29 
asthmatics. Of the asthmatics, 15 subjects had a history of 
mild intermittent asthma and the remainder had mild to 
moderate persistent asthma that was well controlled with 
daily doses of 400-2000 pg inhaled corticosteroids. All 
skiers and intermittent asthmatics had reported asthmatic 
symptoms within the previous year in a self-completed 
questionnaire, and all subjects had bronchial hyper- 
responsiveness to methacholine. For the exhaled NO study, 
the study population consisted of 44 skiers, 29 asthmatics 
and 82 controls. Of the skiers, 9 subjects had bronchial 
hyper-responsiveness to methacholine and asthmatic symp- 
toms. All asthmatic subjects had mild intermittent asthma, 
with asthma symptoms within the previous year, and 
bronchial hyper-responsiveness to methacholine. Control 
subjects did not have a past history of allergic symptoms, 
wheeze or abnormal breathlessness, or use of anti-asthmatic 
medication. 
CLINICAL METHODS 
Asthma symptoms were defined in skiers as wheeze and 
abnormal breathlessness or chest tightness, which was 
present on exertion, exposure to irritants or at rest, and in 
asthmatics as wheeze or abnormal breathlessness with or 
without exposure to pollen, household pets or house dust. 
Ski asthma in skiers was defined as the presence of asthma 
symptoms and bronchial hyper-responsiveness to metha- 
choline. 
Lung function was assessed by flow-volume spirometry 
performed with a pneumotachograph (Master ScopeTM, 
Erich Jaeger GmbH&CoKG, Wtirzburg, Germany) or a 
turbine spirometer (Microlab 3300 Mk2 spirometer, Micro 
Medical Ltd, Gillingham, Kent, England). The better of 
two measurements of ,forced expiratory volume in 1 s 
(FEVt) with less than 5% variation was recorded at 
baseline and during bronchial provocation testing. Baseline 
values were expressed as a percentage of predicted normal 
values (European Coal and Steel Community/Zapletal 
reference values). 
Bronchial responsiveness to methacholine and AMP was 
performed with a controlled tidal volume breathing 
technique and an inhalation synchronized dosimetric jet 
nebulizer. Provocation testing with methacholine was 
performed in all subjects in both study populations. For 
skiers in both studies, and asthmatics in the AMP study, the 
protocol consisted of a cumulative dose of 9.1 pm 
01 (1800 pg) methacholine administered with the Spira 
Elektro 2 nebulizer (Respiratory Care Centre, Hameenlin- 
na, Finland), as previously described (2). For asthmatic and 
control subjects in the exhaled NO study, the protocol 
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consisted of a cumulative dose of 10.1 pmol (2000 pg) 
methacholine delivered in five increments with the Medi- 
cAid jet nebuliser and the Aerosol Provocation System 
(APS, Jaeger). Subjects in the AMP study were tested on 2 
separate days over a period of 2 weeks, with methacholine 
provocation on the first day. Provocation with AMP 
(Sigma Chemicals, St. Louis, MO, U.S.A.) was performed 
with solutions in concentrations of 25 and 250 mg ml-’ 
freshly prepared in saline. The protocol consisted of a 
cumulative dose of 145.4 pmol (50 500 ug), delivered in six 
increments with the Spira Elektro 2 nebulizer. Prior to 
bronchial provocation testing, short-acting /3z-agonists 
were withheld for at least 8 h and long-acting /&agonists, 
cromolyns and theophylline were withheld for at least 24 h. 
Short-acting systematic anti-histamines were withheld for 
at least 24 h prior to AMP provocation. The challenge was 
discontinued if FEVi declined by 20% or more during the 
protocol. Bronchial hyper-responsiveness was defined as 
the cumulative dose that caused a decline in FEVi by 20% 
or more (PDzaFEVi) from baseline. The PDZOFEVl was 
determined by interpolation of the last two points on the 
log dose-response plot. The PD2cFEVimethacholine was 
defined as < 9.1 pmol (1800 pug) with the Spira Elektro 2 
nebulizer and 5 10.1 pmol (2000 pug) with the MedicAid 
nebulizer, and PD20 FEVi AMP was defined as 5 145.4 pmol 
(50 500 pg). Bronchial responsiveness was expressed as the 
dose-response ratio (DRR), which is the % fall in FEVi 
pmol-’ of the provocation agent (22). 
Serum was screened for the presence of specific IgE 
antibodies to eight common inhalant allergens (grass and 
birch pollen, mugwort, moulds, cat, dog and horse dander, 
and house dust mite) with the AlaTOP microtitre plate 
method (Diagnostics Products Corp., Los Angeles, CA, 
U.S.A.). 
EXHALED NITRIC OXIDE (EN01 
MEASUREMENT 
NO concentration in the exhaled air was measured, prior to 
methacholine provocation, by the chemiluminescence 
method with LR 2000 nitric oxide gas analyser (Logan 
Research Ltd., Rochester, U.K.), as previously described 
(23). After calibration and autozeroing, subjects performed 
standardized exhalation from total lung capacity to residual 
volume against a target resistance of 45 cm Hz0 and at an 
expiratory flow rate of 250 ml set-‘, with the help of a 
biofeedback monitor. The level of exhaled NO was based 
on analysis of the plateau portion of the exhaled NO curve 
and the average value of duplicate measurements was used 
for analysis. 
STATISTICAL ANALYSIS 
Data on lung function are presented as mean + SD values 
and analysed for statistical significance with one-way 
ANOVA and Bonferroni’s multiple comparison test. 
Bronchial responsiveness and hyper-responsiveness, and 
exhaled NO levels are presented as median values with 
interquartile ranges (IQR) and analysed for statistical 
significance with Mann-Whitney U-test or Kruskal Wallis 
test with Dunn’s multiple comparison test, as appropriate. 
Correlation coefficients were calculated using Spearman’s 
rank method. Statistical significance was defined as a P 
value of less than 0.05. 
Results 
AMP STUDY 
Neither the PDaa FEVi nor the dose response ratio for 
methacholine was significantly different in the three groups 
(Figs 1 and 2). In contrast, only five of 18 skiers were hyper- 
responsive to AMP, compared to six of 15 non-steroid- 
treated and 10 of 14 steroid-treated asthmatics. Of the 
skiers who tested positive, three were atopic on screening. 
The responsiveness to AMP was increased in order of 
magnitude from ski asthma < non-steroid-treated < 
steroid-treated asthma (Fig. 2) 
Baseline FE& (% predicted) was normal in all three 
groups. FEVi was lower in the steroid-treated than in the 
non-steroid-treated asthmatics (P-=10.05) prior to bronchial 
provocation (Table 1). 
EXHALED NO STUDY 
Exhaled NO concentrations in skiers were not significantly 
different to those in controls [median (IQR) 6.5 (4. I-9.9) vs. 
5.2 (4.2-6.5) ppb]. In asthmatics, the exhaled NO was three- 
fold greater than in skiers [median (IQR) 19.2 (5.1-25.6) 
ppb, PcO.01 (Fig. 3). 
Exhaled NO was three-fold greater in asthmatics than in 
skiers with ski asthma (Fig. 4). There were no significant 
differences between skiers with and without ski asthma 
[median (IQR) 5.3 (2.8-6.9) vs. 7.2 (4.1-9.9) ppb]. Exhaled 
NO was two-fold greater in atopic than non-atopic skiers 
P= 0.06 
ski asthma Asthma- ASthb 
FIG. 1 Bronchial hyper-responsiveness to methacholine 
in skiers and asthmatics. Asthma - : non-steroid treated 
asthmatics, asthma +: steroid-treated asthmatics. 
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FIG. 2 Dose response ratio for (a) methacholine and (b) 
AMP in skiers and asthmatics. Abbreviations as in FIG. 1. 
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FIG. 3 Exhaled NO concentration in controls, skiers and 
asthmatics. Data presented as box and whiskers, Kruskal 
Wallis test with Dunn’s multiple comparison test. 
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FIG. 4 Exhaled NO concentration in skiers with ski 
asthma and asthmatics. Horizontal bars -: median 
values; Mann-Whitney U-test for statistical significance. 
and four-fold greater in atopic than non-atopic asthmatics 
(Fig. 5). 
Baseline FEVi (% predicted) was normal in all groups 
and was lower in skiers than in asthmatics and controls 
(Table 1). Nine (21%) skiers and all asthmatics were hyper- 
responsive to methacholine with a median (IQR) PDzO 
FEV, of 3.5 (1.1-6.1) and 0.9 (0~3-3.1) pmol, respectively. 
The maximum individual PD20 FEVi was 6.7 umol in skiers 
and 7.81 pmol in asthmatics. The DRR for methacholine 
was lower in skiers than in asthmatics [median (IQR) 0.7 
(04-1.3) vs. 15.8 (6.3-4&l), P<O.OOl] and was not 
different from in controls [0.9 (O&1.4)]. Within the skier 
and asthmatic groups, DRR was not significantly different 
between subjects with and without atopy. 
Of the three groups, exhaled NO concentration was 
significantly correlated to the dose response ratio (DRR) 
for methacholine in asthmatics only (N= 29, rho=O.57, 
P< 0.01). Within the asthmatic group, the correlation 
between these two variables was significant in atopic 
subjects only (Fig. 6). 
Discussion 
In the present study, we have investigated two indirect 
markers of asthmatic airway inflammation in competitive 
cross-country skiers with ski asthma. Concomitant hyper- 
responsiveness to AMP was present in 28% of skiers with 
ski asthma and 55% of asthmatics. While exhaled NO was 
significantly increased in asthmatics only, we were unable to 
demonstrate any significant difference in exhaled NO 
concentration between skiers, with or without ski asthma, 
from that in healthy controls. 
AMP is rapidly converted after inhalation to adenosine. 
In both atopic and non-atopic asthmatics, adenosine reacts 
with purine receptors located on the surface of pre- 
activated mast cells with an increased release of mediators 
NON-INVASIVE EVALUATION OF JNFLAMMATION IN SKIERS AND ASTHMATICS 723 
(4 
IOO- 
s 
.B 
-0” 
i E 10- 
8 
i 
l- 
(b) 
loo- 
Skiers 
P < 0.001 
Atopic 
Asthmatics 
P < 0.01 
. 
. 
..*: . . . 
-**- 
. 
. 
. . . 
. 
- l .* . 
l 
Nonatopic Atopic 
FIG. 5 Exhaled NO concentration in (a) skiers and (b) 
asthmatics by atopic status. Horizontal bars: median 
values, Mann-Whitney U-test for statistical significance. 
such as histamine, prostanoids and leukotrienes 
(10,24,25,26). Hyper-responsiveness to AMP is considered 
to be specific for asthmatic subjects (27), but bronchocon- 
striction has been observed in non-asthmatic subjects with 
atopy after administration of a 25-fold greater dose of 
AMP than methacholine on a molar basis (28). While seven 
of 18 skiers (39%) were atopic, three of five AMP 
responders had atopy. A higher prevalence of atopy was 
observed in both asthmatic groups (69%). As the maximal 
administered dose of AMP in the present study was only 
16-fold greater than methacholine on a molar basis, it is 
unlikely that the hyper-responsiveness in these skiers was 
due to an excessive dose of AMP. If the mechanism 
underlying the bronchoconstriction of AMP in skiers is 
similar to that in asthmatics, the present study would 
suggest that a minority of skiers with ski asthma have pre- 
activated airway mast cells. 
,” 1000 
’ * 
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1 10 100 
Exhaled NO concentration (ppb) 
FIG. 6 Correlation of dose response ratio (DRR) for 
methacholine with exhaled NO concentration in atopic 
asthmatics. 
The present study also suggests that additional informa- 
tion may be obtained with AMP challenge. Although we 
were not able to demonstrate any difference in bronchial 
responsiveness to methacholine in the three groups, we did 
demonstrate differences in responsiveness to AMP between 
the groups. Skiers had the lowest bronchial responsiveness 
to AMP, suggesting that the degree or type of airway 
inflammation in ski asthma is different from that present in 
mild intermittent asthma. It has been shown that inhaled 
budesonide has a greater effect on AMP-induced, than on 
methacholine-induced, bronchoconstriction in asthma, 
probably by reducing mast cell numbers and/or function 
(29). We have recently performed a placebo-controlled 
treatment study with inhaled budesonide. In that study we 
were unable to demonstrate any beneficial effect of inhaled 
budesonide treatment in skiers with ski asthma (submitted 
for publication). Whether responsiveness to AMP may 
define a subgroup of ski asthma subjects that may benefit 
from treatment remains to be clarified. However, even 
though the responsiveness of asthmatics to AMP has been 
shown to be reduced by inhaled corticosteroid treatment, it 
is of interest to note that the steroid-treated asthmatic 
group in the present study also had the greatest respon- 
siveness to AMP. The reason for this is unknown, as these 
asthmatics were clinically apparently well controlled, and 
their lung function was within normal limits. 
To our knowledge, hyper-responsiveness to this agent 
has not been reported in endurance athletes with asthma 
symptoms and methacholine hyper-responsiveness. De- 
monstration of hyper-responsiveness to AMP in 28% of 
skiers with ski asthma further supports our previous 
observation of a tendency to a greater degree of bronchial 
inflammation at bronchoscopy, in those skiers with ski 
asthma, and of an increased mast cell count in the 
bronchoalveolar lavage fluid of skiers compared to controls 
(30). 
In contrast, although confirming previous observations 
of increased exhaled NO levels in asthmatics, the present 
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study suggests that NO appears to be of less value as a 
surrogate marker of inflammation in ski asthma, than it is 
in allergic asthma. Exhaled NO was consistently greater in 
atopic than non-atopic subjects in both groups, and a 
significant correlation with bronchial responsiveness was 
observed in atopic asthmatics only. Of the six skiers and 15 
asthmatics with exhaled NO in excess of 15 ppb (Fig. 4), all 
were atopic, with five skiers and all asthmatics sensitized to 
perennial allergens, and with the remaining skier sensitised 
to grass pollen. The finding of an elevated exhaled NO 
concentration in atopic subjects in the present study is in 
accordance with other studies of asthmatic and non- 
asthmatic subjects with atopy (3 1,32). As allergic symptoms 
are less prevalent in skiers with asthmatic symptoms and 
methacholine hyper-responsiveness (21) measurement of 
exhaled NO has a limited place in the diagnosis and 
monitoring of the effect of treatment. 
In addition to inflammatory changes at bronchoscopy, 
we have observed an inflammatory infiltrate in the mucosa 
of the proximal airways in a biopsy study of skiers 
(submitted for publication). An elevated NO concentration 
in asthmatics is associated with increased expression of 
inducible NO synthase (33). The absence of an elevated 
exhaled NO concentration in skiers raises the possibility 
that the airway inflammation in these athletes may be 
mediated by mechanisms other than those believed to be 
operating in allergic asthma. 
In summary, bronchial challenge with AMP indicate a 
difference between skiers with ski asthma and atopic 
asthma, with the presence of pre-activated mast cells being 
a less prominent feature in ski asthma. Exhaled NO was not 
elevated in ski asthma, and appears to be more useful as a 
marker of atopic status than as a marker of inflammation in 
skiers. 
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